Application of Nanoparticle Technology for the Prevention of Restenosis After Balloon Injury in Rats

&NA; Restenosis after percutaneous coronary intervention continues to be a serious problem in clinical cardiology. Recent advances in nanoparticle technology have enabled us to deliver an antiproliferative drug selectively to the balloon‐injured artery for a longer time. NK911, which is a core‐shell nanoparticle of polyethyleneglycol‐based block copolymer encapsulating doxorubicin, accumulates in vascular lesions with increased permeability. We first confirmed that balloon injury caused a marked and sustained increase in vascular permeability (as evaluated by Evans blue staining) for a week in the rat carotid artery. We then observed that intravenous administration of just 3 times of NK911, but not doxorubicin alone, significantly inhibited the neointimal formation of the rat carotid artery at 4 weeks after the injury in both a single‐ and double‐injury model. Immunostaining demonstrated that the effect of NK911 was due to inhibition of vascular smooth muscle proliferation but not to enhancement of apoptosis or inhibition of inflammatory cell recruitment. Measurement of vascular concentrations of doxorubicin confirmed the effective delivery of the agent to the balloon‐injured artery by NK911 in both a single‐ and double‐injury model. RNA protection assay demonstrated that NK911 inhibited expression of several cytokines but not that of apoptosis‐related molecules. NK911 was well tolerated without any adverse systemic effects. These results suggest that nanoparticle technology to target vascular lesions with increased permeability is a promising and safe approach for the prevention of restenosis after balloon injury. The full text of this article is available at http://www.circresaha.org. (Circ Res. 2003;92:e62‐e69.)

[1]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[2]  T. Okano,et al.  Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. , 1999, Journal of drug targeting.

[3]  H. Maeda.  Role of Microbial Proteases in Pathogenesis , 1996, Microbiology and immunology.

[4]  H. Maeda,et al.  Activation of hageman factor and prekallikrein and generation of kinin by various microbial proteinases. , 1989, The Journal of biological chemistry.

[5]  Vladimir P. Torchilin,et al.  Accumulation of Protein-Loaded Long-Circulating Micelles and Liposomes in Subcutaneous Lewis Lung Carcinoma in Mice , 1998, Pharmaceutical Research.

[6]  D. Neuberg,et al.  High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  W. Kolch,et al.  Comparison of anthracycline-induced death of human leukemia cells: Programmed cell death versus necrosis , 2002, Apoptosis.

[8]  Y. Sugiyama,et al.  Cisplatin-Loaded Polymer-Metal Complex Micelle with Time-Modulated Decaying Property as a Novel Drug Delivery System , 2001, Pharmaceutical Research.

[9]  Krishnendu Roy,et al.  Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy , 1999, Nature Medicine.

[10]  T. Fujiwara,et al.  p53 inhibits adriamycin-induced down-regulation of cyclin D1 expression in human cancer cells. , 2002, Biochemical and biophysical research communications.

[11]  H. Maeda,et al.  Kallikrein-kinin in infection and cancer. , 1999, Immunopharmacology.

[12]  D. Grandér,et al.  Activation of Bak, Bax, and BH3-only Proteins in the Apoptotic Response to Doxorubicin* , 2002, The Journal of Biological Chemistry.

[13]  T. Takeuchi,et al.  A high performance liquid chromatographic method of analysis of 4'-O-tetrahydropyranyladriamycin and their metabolites in biological samples. , 1983, The Journal of antibiotics.

[14]  E. Topol,et al.  Neointimal Hyperplasia After Arterial Injury Is Increased in a Rat Model of Non–Insulin-Dependent Diabetes Mellitus , 2001, Circulation.

[15]  Yokoyama Masayuki,et al.  Block copolymer micelles as vehicles for drug delivery , 1993 .

[16]  M. Jones,et al.  Polymeric micelles - a new generation of colloidal drug carriers. , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[17]  I. Fishbein,et al.  Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Teruo Okano,et al.  Block copolymer micelles for drug delivery: Loading and release of doxorubicin , 1997 .

[19]  M. Leon,et al.  Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. , 1996, Circulation.

[20]  H. Peterson,et al.  Experimental studies on the uptake and rentention of labelled proteins in a rat tumour. , 1973, European journal of cancer.

[21]  D. Stuart,et al.  Targeted delivery of antisense oligonucleotides in cancer. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[22]  G. Kwon,et al.  The effect of fatty acid substitution on the in vitro release of amphotericin B from micelles composed of poly(ethylene oxide)-block-poly(N-hexyl stearate-L-aspartamide). , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[23]  T. Okano,et al.  Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. , 1991, Cancer research.

[24]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[25]  M. Morimatsu,et al.  Role of Rho-Associated Kinase in Neointima Formation After Vascular Injury , 2001, Circulation.

[26]  N K Hollenberg,et al.  Persistent dysfunction of regenerated endothelium after balloon angioplasty of rabbit iliac artery. , 1990, Circulation.

[27]  Atsushi Harada,et al.  Spontaneous Formation of Polyion Complex Micelles with Narrow Distribution from Antisense Oligonucleotide and Cationic Block Copolymer in Physiological Saline , 1996 .

[28]  T. Okano,et al.  Improved synthesis of adriamycin-conjugated poly (ethylene oxide)-poly (aspartic acid) block copolymer and formation of unimodal micellar structure with controlled amount of physically entrapped adriamycin , 1994 .

[29]  J. Bittl,et al.  Advances in coronary angioplasty. , 1996, The New England journal of medicine.

[30]  T. Okano,et al.  Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[31]  T. Okano,et al.  Development of the polymer micelle carrier system for doxorubicin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[32]  H. Kaplan,et al.  Effect of antineoplastic agents on gamma-interferon production in human peripheral blood mononuclear cells. , 1984, Cancer Research.

[33]  W. J. van der Giessen,et al.  Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. , 1998, Journal of the American College of Cardiology.

[34]  J. Robert,et al.  Doxorubicin-induced alterations of c-myc and c-jun gene expression in rat glioblastoma cells: role of c-jun in drug resistance and cell death. , 1998, Biochemical pharmacology.

[35]  T. Okano,et al.  Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[36]  Teruo Okano,et al.  Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-Adriamycin conjugates , 1994 .

[37]  Y. Sugiyama,et al.  Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[38]  J. Turk,et al.  Effect of anticancer drugs on the release of interleukin-6 in vitro , 2005, Cancer Immunology, Immunotherapy.

[39]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[40]  Yokoyama Masayuki,et al.  Polymer micelles as novel drug carrier: Adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer , 1990 .

[41]  K. Kataoka,et al.  Temperature-related change in the properties relevant to drug delivery of poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles in aqueous milieu. , 2002, Journal of controlled release : official journal of the Controlled Release Society.